Case Study: Accelerating Vaccine Access in a Post COVID-19 Environment
The Republic of Indonesia's proactive approach to child health, marked by the introduction of the Pneumococcal Conjugate Vaccine (PCV) in September 2022 and the Rotavirus Vaccine (RVV) in December 2022 across 17 districts in 14 provinces, showcases a strategic defense against the prevalent threats of pneumonia and diarrheal diseases, and a strong commitment to safeguarding child health. The concurrent introduction of these two vaccines within a year illustrates Indonesia's capacity to adapt and strategize effectively against logistical and healthcare challenges, laying a foundation for future public health endeavors.
In pursuit of documenting and analyzing this landmark effort, the Global Advocacy for PCV (GAP) project conducted six semi-structured interviews with national and sub-national staff from the Clinton Health Access Initiative (CHAI) in Indonesia, highlighting critical enablers and opportunities that have underpinned Indonesia’s successful vaccination initiatives, offering valuable lessons for global health stakeholders considering similar concurrent vaccine introductions. Key enablers included strong political commitment, improved electronic data systems, and enhanced healthcare services. The initiative also leveraged private sector engagement and innovative approaches, such as integrated vaccine delivery and health worker training.
This case study offers valuable insights for global health stakeholders on overcoming challenges and optimizing vaccine rollouts in similar contexts, promoting resilience and equity in immunization efforts worldwide.